Nota de prensa



Trial Data to Support Regulatory Submission to U.S. Food and Drug Administration

• Ysios Capital led the 15M€ Series A round in 2017 in an international investors syndicate with Innogest and Omega Funds

Anaconda Biomed, a medical technology company developing a next-generation thrombectomy system for the treatment of ischemic stroke, and owned by venture capital firm Ysios Capital, has announced the completion of initial patient cases in a first-in-human study at Hospital Vall d’hebron in Barcelona. This 125-patient, prospective, multi-center study will assess system safety and reperfusion measured using the modified treatment in cerebral infarction (mTICI) score. Study data will be used to support a regulatory submission to the U.S. Food and Drug Administration.

“This first-in-human study is an important step forward for Anaconda Biomed as we look to demonstrate the efficacy of our Advanced Thrombectomy System,” explained Francois Salmon, CEO of Anaconda Biomed. “We are hoping this study will clinically replicate in vitro testing that has shown our system enables a quick, effective yet safe endovascular treatment for patients suffering from a major ischemic stroke. Our mission is to minimize the risk of death and disability following a stroke, and we look forward to using the study results to move us closer to bringing this new alternative to patients.”

Dr. Marc Ribo performed the study’s first case at Vall d’Hebron.

“With the first study participants completed, we are beginning to gather results that will enable us to establish an mTICI score for Anaconda’s thrombectomy system,” stated Dr. Alejandro Tomasello, principal investigator of the study and head of the neurointerventional department at Vall d’Hebron. “This study is looking at how effective this system is in overcoming the limitations of other approaches. Typically, difficulties with distal blood flow arrest and clot fragmentation to no- or low-reperfusion at first pass have limited the success of other systems. As this study expands to additional centers and additional patients, we anticipate a robust and conclusive set of data.”

Anaconda’s Advanced Thrombectomy System consists of a delivery catheter, a unique, funnel-shaped aspiration catheter, and a stent retriever. When deployed, the funnel self-expands and directly conforms to the artery diameter up to 5mm. It is designed to locally arrest flow and allow full thrombus extraction without fragmentation. The ongoing, in-human study aims to validate earlier testing that achieved statistically significant improvement in revascularization rates at both first and third pass.

About Anaconda Biomed

Anaconda Biomed is a medical technology company dedicated to developing next-generation thrombectomy systems for the treatment of ischemic stroke. Its flagship product is the Advanced Thrombectomy System. Anaconda Biomed has received funding from leading life science investment firms Ysios Capital, Omega Funds, and Innogest, as well as Banco Sabadell and private investors. The company has also received public support from Enisa, Neotec (CDTI) and EIT Health public grants. The Advanced Thrombectomy System is an investigational device and is not available for sale in the United States or in the European Union. For more information, visit https://anaconda.bio/.

About Ysios Capital
Ysios Capital is a leading Spanish independent venture capital firm that provides private equity financing to early- and mid-stage human healthcare and life science companies. We target the biotechnology industry, with an exclusive focus on therapeutics. Founded in 2008, Ysios Capital has € 191,4 million in assets under management through its two funds: Ysios BioFund I (€65 M) and Ysios BioFund II Innvierte (€ 126M).

Nuevos informes y series de datos: El Capital riesgo Informal en España 2019 /  Informe de Impacto Económico y Social del Capital Privado en las operaciones de Middle Market en España. 2018 (ASCRI) / Informe de Impacto Económico y Social de los préstamos otorgados por Enisa

Otros informes destacados: Madurez del Venture Capital en España. Hechos relevantes y detalle de más de 60 casos de éxito desde los años 90 hasta la actualidad… Also in english / Financiación de startups de Energía en España / El Préstamo Participativo como herramienta para el arranque de empresas en España / El tiempo de las desinversiones en Private Equity en España (Also in english)

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos requeridos están marcados *

Publicar comentario